<DOC>
	<DOCNO>NCT01844791</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy use OCZ103-OS combination Platinum-Gemcitabine base doublet first line therapy stage IV non-small cell lung cancer ( NSCLC ) patient .</brief_summary>
	<brief_title>An Exploratory Study OCZ103-OS Combination With Standard Care Stage IV Non-Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description>This single arm , open label study investigate safety efficacy use OCZ103-OS combination Platinum-gemcitabine base doublet first line therapy stage IV non-small cell lung cancer ( NSCLC ) patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>Written Informed Consent ; Males females ; 1875 year ; Histologically cytologically confirm stage IV NSCLC patient eligible platinumgemcitabine base doublet therapy ( M1a M1b , seventh edition descriptor Revised International System Staging Lung Cancer , adopt AJCC . ) Patients prior diagnosis stage IIIa IIIb NSCLC progress stage IV also eligible ; ECOG performance 0 1 ; One tumor lesion measurable RECIST criterion version 1.1 , CT scan MRI ; Patients previous radiotherapy definitive therapy locally advance nonsmall cell lung cancer eligible , long select measurable lesion outside original radiation therapy port unless demonstrate progression lesion . Radiation therapy must complete &gt; 4 week prior study entry ; Palliative radiotherapy must complete &gt; 2 week prior study entry . Concomitant palliative radiotherapy exist bone lesion pain control allow ; Life expectancy least 3 month Any prior systemic therapy recurrent metastatic NSCLC , except prior neoadjuvant adjuvant systemic chemotherapy NSCLC administer least 6 month prior enrolment ; Any follow condition : Ongoing cardiac dysrhythmias NCI CTCAE grade â‰¥ 2 ; atrial fibrillation grade ; QTc interval &gt; 450 msec male &gt; 470 msec female uncontrolled intercurrent illness , e.g . unstable angina ; severe coronary disease , ventricular arrhythmia , bradycardia &lt; 50 bpm ; history additional risk factor torsades de pointes ( e.g. , heart failure , hypokalemia family history Long QT Syndrome ) ; Systolic Blood Pressure &lt; 100 mmHg ( deem clinically significant treat physician ) ; Uncontrolled diabetes . Patients well control diabetes , HbA1C le 7 % , stable hypoglycaemic therapy diet , eligible ; Clinically significant renal impairment chronic pancreatitis ; History clinically significant hypoglycemia , fast blood glucose &lt; 3 mmol/L ; Inadequate baseline organ function show follow laboratory value : Hemoglobin &lt; 100 g/L Absolute neutrophil count &lt; 1.5 x 10e9/L Platelet count &lt; 100 x 10e9/L Total bilirubin &gt; 1.5 x ULN AST ALT &gt; 2.5 x ULN &gt; 5 ULN presence liver metastases Serum creatinine &gt; 1.5 x ULN calculate creatinine clearance &lt; 60 ml/min To dependent oxygen treatment ; Active infection require antibiotic ; A major surgical procedure , open biopsy , significant traumatic injury within 28 day begin treatment , anticipation need major surgery course study ; Pregnancy breastfeed . All woman childbearing potential must negative pregnancy test prior first receive protocol therapy ; Active alcohol drug abuse ; Known suspect allergy/hypersensitivity agent give course trial ; Any comorbid condition judgment investigator render subject high risk treatment complication reduce probability assess clinical effect ; Other malignancy diagnose within last 5 year exception Basal Cell Carcinoma skin ; Patients unable comply study protocol followup schedule psychological , familial , sociological geographical reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>OCZ103-OS</keyword>
	<keyword>Pentamidine bi ( 2-hydroxyethanesulfonate )</keyword>
	<keyword>platinum-gemcitabine base doublet first line therapy</keyword>
</DOC>